Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6515025 | 0.86 | CYP1A2 (0.53) | KDM4EHSD17B10CYP1A2ALDH1A1PDE3B | |
| SCHEMBL15042816 | 0.84 | KDM4E (0.50) | KDM4EHSD17B10LMNACYP1A2ADORA3 | |
| SCHEMBL24312996 | 0.84 | KDM4E (0.41) | KDM4EHSD17B10LMNACYP1A2ADORA3 | |
| SCHEMBL6753935 | 0.83 | SCN10A (0.38) | KDM4EHSD17B10CYP1A2ALDH1A1PDE3B | |
| SCHEMBL13542739 | 0.82 | KDM4E (0.40) | KDM4EHSD17B10LMNACYP1A2ADORA3 | |
| SCHEMBL22962142 | 0.82 | KDM4E (0.40) | KDM4EHSD17B10LMNACYP1A2ADORA3 | |
| SCHEMBL5201662 | 0.78 | KDM4E (0.46) | KDM4EHSD17B10LMNAADORA3ADORA2A | |
| SCHEMBL353027 | 0.76 | ALDH1A1 (0.41) | KDM4EHSD17B10LMNAADORA3ALDH1A1 | |
| SCHEMBL12328110 | 0.75 | TYMS (0.43) | KDM4EHSD17B10LMNACYP1A2ADORA3 | |
| SCHEMBL12328106 | 0.75 | HSD17B10 (0.44) | KDM4EHSD17B10LMNACYP1A2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0428260-B1 | Metal surface treatment agents | SANWA LAB LTD (JP) | 2000-01-05 | — | — | EP | claimed |
| EP-0562187-B1 | Process for production of copper through-hole printed wiring boards | SANWA LAB LTD (JP) | 1996-01-10 | — | — | EP | claimed |
| US-5275694-A | Printed circuits with copper through holes, negative patterns, photoresists, lamination, dipping and etching | SANWA LABORATORY LTD. (JP) | 1994-01-04 | — | — | US | claimed |
| EP-0562187-A1 | Process for production of copper through-hole printed wiring boards | SANWA LABORATORY LTD. (JP) | 1993-09-29 | — | — | EP | claimed |
| EP-0428260-A2 | Metal surface treatment agents | SANWA LABORATORY LTD. (JP) | 1991-05-22 | — | — | EP | claimed |
| US-8183276-B2 | Therapeutic agents | MERCK SHARP & DOHME CORP. | 2012-05-22 | — | — | US | disclosed |
| US-20100324029-A1 | THERAPEUTIC AGENTS | MERCK SHARP & DOHME CORP. | 2010-12-23 | — | — | US | disclosed |
| US-7652023-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-6712262-B2 | BENZIMIDAZOLE AND IODINE COMPOUNDS | TAMURAKAKEN CORPORATION (JP) | 2004-03-30 | — | — | US | disclosed |
| US-20030141351-A1 | Water-soluble preflux, printed circuit board, and process for treating the surface of a metal in a printed circuit board | TAMURA CORPORATION (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-0428260-B1 | Metal surface treatment agents | SANWA LAB LTD (JP) | 2000-01-05 | — | — | EP | disclosed |
| EP-0562187-B1 | Process for production of copper through-hole printed wiring boards | SANWA LAB LTD (JP) | 1996-01-10 | — | — | EP | disclosed |
| US-5275694-A | Printed circuits with copper through holes, negative patterns, photoresists, lamination, dipping and etching | SANWA LABORATORY LTD. (JP) | 1994-01-04 | — | — | US | disclosed |
| EP-0562187-A1 | Process for production of copper through-hole printed wiring boards | SANWA LABORATORY LTD. (JP) | 1993-09-29 | — | — | EP | disclosed |
| EP-0428260-A2 | Metal surface treatment agents | SANWA LABORATORY LTD. (JP) | 1991-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | KDM4E 1618/4885HSD17B10 255/4885LMNA 170/4885 |
| US-20100324029-A1 | THERAPEUTIC AGENTS | PSEN2, PSEN1, BACE2 | KDM4E 3970/4885HSD17B10 1886/4885LMNA 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.